Identifying biomarkers in patients with skin lymphomas.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify prognostic and treatment-predictive biomarkers in patients diagnosed with Mycosis Fungoides and Sézary Syndrome. It involves blood tests and analyses of the lymphoma microenvironment, skin barrier, and skin microbiology profile. The study includes patients aged 18 to 100 years with confirmed stages I-IV of these conditions. By understanding these biomarkers, the study seeks to enhance treatment strategies for affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-100 years
* Histologically confirmed (according to the World Health Organization (WHO)/EORTC classification) MF/SS stages I-IV
* WHO performance status 0 -3
* Absence of psychiatric illness or condition which could interfere with the subjects' ability to understand the requirements of the study.
* Written informed consent according to International Conference on Harmonization (ICH)/(Good Clinical Practice (GCP), and Swedish regulations
* No minimum or maximum required routine laboratory data

Exclusion Criteria:

Not applicable. No exclusion criteria are specified.

Where it's running

• Lund University Hospital
  Lund, Sweden Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Poteligeo (mogamulizumab) for adults with mycosis fungoides or Sézary syndrome

  This project will try Poteligeo (mogamulizumab) in adults with mycosis fungoides or Sézary syndrome who have had at least one prior systemic therapy to see how safe and effective it is in routine care in Korea.

  Recruiting at 5 sites Kyowa Kirin Co., Ltd. · Busan, Busan Metropolitan City and 5 other locations · NCT07132567

• Registry for individuals with T-cell lymphoma

  This study is gathering information from people with T-cell lymphoma to help researchers learn more about the disease and improve treatments.

  Recruiting at 6 sites Memorial Sloan Kettering Cancer Center · Duarte, California and 25 other locations · NCT05978141

• Combining mogamulizumab with low-dose total skin electron beam therapy for treating skin lymphomas

  This study is testing if combining a new drug called mogamulizumab with a special type of skin radiation therapy can help people with certain skin lymphomas feel better.

  Recruiting Phase 2 Stanford University · Stanford, California · NCT04256018

• Collection of blood, urine, and tissue samples for research on skin conditions

  This study is collecting blood, urine, and tissue samples from people with skin conditions like cutaneous T-cell lymphoma, eczema, and atopic dermatitis to help improve treatments in the future.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT00177268

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.